BOSTON– Amplitude Vascular Systems (AVS), a medical device company developing therapies for severely calcified arterial disease, has opened its new global headquarters in Waltham, Mass., quadrupling its operational capacity ahead of an anticipated U.S. commercial launch.
The 37,811-square-foot facility at 180 Third Avenue will serve as the company’s hub for research and development, manufacturing and corporate operations. The site will support the advancement of AVS’s flagship technology, the PULSE intravascular lithotripsy (IVL) system, designed to treat both peripheral and coronary artery disease.
“Waltham/Greater Boston is one of the most vibrant hotbeds for innovation in the country and provides significant advantages in recruiting the best talent,” said Mark Toland, Chairman of the Board of AVS. “As we continue to build momentum toward regulatory approval in the U.S., the new space will support the company’s growth to bring the next generation intravascular lithotripsy therapy for both peripheral and coronary artery disease to market.”
Waltham Mayor Jeannette McCarthy welcomed the company to the city, noting its presence adds to the region’s growing life sciences cluster. “AVS is joining a thriving hub for cutting-edge life sciences companies in Waltham and we are proud to welcome them to the city,” McCarthy said. “The company’s growth and approaching milestones will create quality job opportunities for our community and we look forward to seeing their continued success.”
The company’s expansion comes after a series of milestones since establishing its first headquarters in Boston’s Seaport in 2023. AVS secured Investigational Device Exemption approval in June 2024 to begin the POWER PAD II pivotal study evaluating its PIVL system in femoropopliteal arteries. That study began in October 2024 and is expected to conclude in 2025, with primary endpoints to be presented as a late-breaking clinical trial at the VIVA Conference in November 2025. The company also raised $36 million in Series B financing earlier this year to support its clinical programs and development of a coronary platform.
“The new headquarters is a testament to our progress as we grow our team and prepare to bring our innovative solution to managing calcified arterial disease to the market,” said Sean Gilligan, Chief Operating Officer of AVS. “The dedicated R&D and operations spaces have helped accelerate our team’s capabilities and our manufacturing strategy as we prepare for commercialization of our first platform in mid-2026.”
The new facility, part of a multi-tenant building completed in 2023, provides access to public transit, major highways and Logan Airport.
